VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Viatris Inc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$18.26−0.39 (-2.12%)

Close on Oct 19, 2026

Market cap: $21.24B
P/E (TTM): –
Dividend yield: 2.63%

Fundamental chart

Pick a measure to chart its full history

$14.30BFY2025, +3.2% a year since FY2018

Where these numbers come from

Parsed from the XBRL in Viatris's annual and quarterly filings with the SEC
Per-share figures adjusted for the 3-for-2 split on Oct 9, 2003
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VTRS.

Revenue growth4.4% · median -0.5%

Gross margin34.8% · median 64.4%

Operating margin-0.6% · median 9.8%

Company	Revenue	Growth
VTRS	$14.74B	+4.4%
TEVA	$14.10B	-15.2%
BHC	$10.85B	+10.1%
ZTS	$9.52B	+1.5%
OGN	$6.13B	-2.5%
GRFS	–	–

Company

Next earnings (est.): Nov 5, 2026, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 30,000
Held by institutions: 91.5%
Auditor: DELOITTE & TOUCHE LLP
SEC CIK: 1792044

Advertisement
300 × 250